Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

August 15, 2025 updated by: Weerawat Kiddee, Prince of Songkla University

Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Thailand
    • Songkhla
      • Hat-yai, Songkhla, Thailand, 90110
        • Recruiting
        • Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Diagnosis of neovascular glaucoma
  2. The patients having IOP > 21 mmHg, having the indication for trabeculectomy
  3. The patients' age of at least 18-year-old
  4. The patients having visual potential at least hand motion.
  5. Present of NVI or NVA.
  6. Willing and able to provide informed consent to participate in the study
  7. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

Exclusion Criteria:

  1. One eye patient
  2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
  3. Cannot obtain endothelial cell count.
  4. History of bevacizumab or fluorescence dye allergy.
  5. Active infectious ocular disease including endophthalmitis and corneal ulcer
  6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
  7. Has or planning to be pregnant or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intracameral injection
Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intracameral injection
A/C injection of 1.25 mg/0.05 mL bevacizumab
Experimental: Intravitreal injection
Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intravitreal injection
Vitreous injection of 1.25 mg/0.05 mL bevacizumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
regression of nevolascularization
Time Frame: 2 months
Amount of nevolascular of iris and angle regression
2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IOP reduction
Time Frame: 2 months
IOP reduction at 2-month visit compare to baseline
2 months
Injection complication
Time Frame: 2 days
Hyphema, IOP spike
2 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Prince of Songkla University

Investigators

  • Principal Investigator: Assoc.Prof.Weerawat Kiddee, MD, Prince of Songkla University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2018

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

August 24, 2018

First Submitted That Met QC Criteria

August 24, 2018

First Posted (Actual)

August 27, 2018

Study Record Updates

Last Update Posted (Actual)

August 21, 2025

Last Update Submitted That Met QC Criteria

August 15, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REC6100321

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma, Neovascular

Clinical Trials on Intracameral injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe